Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × Steroids × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 3 Prostatic Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Hepatitis 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Chemical and Drug Induced Liver Injury 1 Bone Cysts 1 Anatomic Stage IV Breast Cancer AJCC v8 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Bevacizumab 46 Gemcitabine 45 Cyclophosphamide 41 Carboplatin 37 Docetaxel 35 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 30 Oxaliplatin 26 Radiotherapy 24 Irinotecan 24 Capecitabine 24 Leucovorin 22 Dexamethasone 22 Cetuximab 21 Nivolumab 19 Doxorubicin 19 Pemetrexed 18 Drug Therapy 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 fludarabine 13 atezolizumab 13 Sorafenib 13 Lapatinib 13 Everolimus 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04810156 2022-12-14

I-HEP

Herlev Hospital

Phase 2 Unknown

Hepatitis, Neoplasms, Chemical and Drug Induced Liver Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡